Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA; and the Parkinson's Progression Markers Initiative.

Mov Disord. 2015 Mar 4. doi: 10.1002/mds.26170. [Epub ahead of print]

PMID:
25737166
2.

The Profile of Long-term Parkinson's Disease Survivors with 20 Years of Disease Duration and Beyond.

Hassan A, Wu SS, Schmidt P, Simuni T, Giladi N, Miyasaki JM, Bloem BR, Malaty IA, Okun MS.

J Parkinsons Dis. 2015 Feb 26. [Epub ahead of print]

PMID:
25720446
3.

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM.

JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120.

4.

Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice?

Bega D, Gonzalez-Latapi P, Zadikoff C, Spies W, Simuni T.

Neurodegener Dis. 2015 Jan 15. [Epub ahead of print]

PMID:
25592727
5.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

Smith KM, Eyal E, Weintraub D; ADAGIO Investigators.

JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472.

PMID:
25420207
6.

Effects of endurance exercise training on the motor and non-motor features of Parkinson's disease: a review.

Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM.

J Parkinsons Dis. 2015 Jan 1;5(1):21-41. doi: 10.3233/JPD-140425.

PMID:
25374272
7.

Overcoming obstacles to repurposing for neurodegenerative disease.

Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, Fillit HM.

Ann Clin Transl Neurol. 2014 Jul;1(7):512-8. doi: 10.1002/acn3.76. Epub 2014 Jun 24.

8.

Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).

Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J; STACCATO study investigators.

Pharmacotherapy. 2014 Dec;34(12):1250-8. doi: 10.1002/phar.1500. Epub 2014 Oct 14.

PMID:
25314256
9.

Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.

Carta AR, Simuni T.

Expert Opin Investig Drugs. 2015 Feb;24(2):219-27. doi: 10.1517/13543784.2015.963195. Epub 2014 Sep 17.

PMID:
25227476
10.

Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites.

Stroupe KT, Weaver FM, Cao L, Ippolito D, Barton BR, Burnett-Zeigler IE, Holloway RG, Vickrey BG, Simuni T, Follett KA.

Mov Disord. 2014 Nov;29(13):1666-74. doi: 10.1002/mds.26029. Epub 2014 Sep 15.

PMID:
25220042
11.

A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease.

Bega D, Gonzalez-Latapi P, Zadikoff C, Simuni T.

Curr Treat Options Neurol. 2014 Oct;16(10):314. doi: 10.1007/s11940-014-0314-5.

PMID:
25143234
12.

Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial.

Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators.

J Parkinsons Dis. 2014;4(4):629-38. doi: 10.3233/JPD-140383.

PMID:
25062961
13.

Recognition and treatment of depressive symptoms in Parkinson's disease: the NPF dataset.

Bega D, Wu SS, Pei Q, Schmidt PN, Simuni T.

J Parkinsons Dis. 2014;4(4):639-43. doi: 10.3233/JPD-140382.

PMID:
25035310
14.

Is exenatide the next big thing in Parkinson's disease?

Simuni T, Brundin P.

J Parkinsons Dis. 2014;4(3):345-7. doi: 10.3233/JPD-149001.

PMID:
24748153
15.

A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.

Nicholas AP, Borgohain R, Chaná P, Surmann E, Thompson EL, Bauer L, Whitesides J, Elmer LW; SP921 Study Investigators.

J Parkinsons Dis. 2014;4(3):361-73. doi: 10.3233/JPD-130320.

PMID:
24643203
16.

Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease.

Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, Rademaker AW, Simuni T, Zadikoff C, Zee PC.

JAMA Neurol. 2014 Apr;71(4):463-9. doi: 10.1001/jamaneurol.2013.6239.

17.

Timed up and go, cognitive, and quality-of-life correlates in Parkinson's disease.

Stegemöller EL, Nocera J, Malaty I, Shelley M, Okun MS, Hass CJ; NPF Quality Improvement Initiative Investigators.

Arch Phys Med Rehabil. 2014 Apr;95(4):649-55. doi: 10.1016/j.apmr.2013.10.031. Epub 2013 Nov 27.

PMID:
24291596
18.

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Parkinson Study Group.

Mov Disord. 2013 Nov;28(13):1823-31. doi: 10.1002/mds.25639. Epub 2013 Sep 30.

PMID:
24123224
19.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative.

JAMA Neurol. 2013 Oct;70(10):1277-87.

20.

High rates and the risk factors for emergency room visits and hospitalization in Parkinson's disease.

Hassan A, Wu SS, Schmidt P, Dai Y, Simuni T, Giladi N, Bloem BR, Malaty IA, Okun MS; NPF-QII Investigators.

Parkinsonism Relat Disord. 2013 Nov;19(11):949-54. doi: 10.1016/j.parkreldis.2013.06.006. Epub 2013 Jul 5.

PMID:
23835430
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk